ARVO 2024: Imaging provides insight into the metabolic aspects of glaucoma development


Osamah Saeedi, MD, MS, discusses his poster presentation from the ARVO Imaging in the Eye conference

At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Osamah Saeedi, MD, MS. Dr Saeedi is an Associate Professor of Ophthalmology, Director of Clinical Research and Director of the Glaucoma Division at the University of Maryland School of Medicine in Baltimore, Maryland. Prior to the ARVO annual meeting, he presented a poster at the Imaging in the Eye Conference on 4 May, and took time to share his research with our team.

Editor's note: The below transcript has been lightly edited for clarity.

Osamah Saeedi, MD, MS: I'm at ARVO 2024. Yesterday, I presented at the ARVO Imaging in the Eye Conference; I presented a poster entitled, "The repeatability and reproducibility of fluorescence lifetime imaging ophthalmoscopy (FLIO) and erythrocyte mediated angiography in a non-human primate model." The key findings here are we adjusted intraocular pressure in a non-human, in an acute IOP elevation model, in a nonhuman primate. And what we found essentially that the fluorescence lifetime imaging ophthalmoscopy and erythrocyte mediated angiography were...highly repeatable in this model.

This is particularly important, because both of these modalities are going to give us further insight, potentially, into the metabolic and non-pressure related changes in glaucoma. So we wanted to make sure that they were not affected by intraocular pressure. While this work is early, it is important as glaucoma specialists that we look for biomarkers for the disease that are not related to intraocular pressure. Hence, knowing the metabolic activity of a tissue, knowing the retinal blood flow, may ultimately help us both monitor the disease early on in, the in the process, as well as develop new treatments that are not related to intraocular pressure. So we have now established that these measurements are highly repeatable in this model of glaucoma, and so we will now look at the long-term changes with elevated intraocular pressure chronically in this model.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Marjorie Rah, OD, PhD, FAAO
© 2024 MJH Life Sciences

All rights reserved.